Treatment with Kampo medicine (Keigai-rengyo-to) and Minocycline for Respiratory syncytial virus infection
Treatment with Kampo medicine and Minocycline for Respiratory syncytial virus infection
DOI:
https://doi.org/10.51094/jxiv.3991キーワード:
Respiratory syncytial virus、 Kampo medicine、 minocycline抄録
Respiratory syncytial virus (RSV) causes major global morbidity, yet effective antiviral treatments remain limited. Kampo medicines contain multiple plant‑derived compounds—such as baicalin, glycyrrhizin, luteolin, quercetin, kaempferol, acteoside, phillyrin and rutin—that inhibit RSV replication, modulate interferon responses, and reduce inflammation in experimental models. Non‑Kampo agents including minocycline and micafungin also show antiviral potential. Combining Kampo formulations, such as Keigai‑rengyo‑to, with minocycline may provide synergistic benefit. Repurposing these agents offers a practical strategy for developing RSV therapeutics, particularly for high‑risk adults.
利益相反に関する開示
The authors have no conflicts of interest associated with this article.ダウンロード *前日までの集計結果を表示します
引用文献
Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet. 2017 Sep 2;390(10098):946-58.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. New England Journal of Medicine. 2005 Apr 28;352(17):1749-59.
Wang X, Li Y, O'brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. The Lancet Global Health. 2020 Apr 1;8(4):e497-510.
Wang X, Katte RH, Lu M. RSV vaccine development: advances and fusion protein-focused strategies. Frontiers in Immunology. 2026 Feb 1:1710895.
Hoover J, Eades S, Lam WM. Pediatric Antiviral Stewardship: Defining the Potential Role of Ribavirin in Respiratory Syncytial Virus-Associated Lower Respiratory Illness. J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):372-378. doi: 10.5863/1551-6776-23.5.372. PMID: 30429691; PMCID: PMC6213624.
Takayama S, Namiki T, Arita R, et al. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. Front Pharmacol. 2022 Nov 9;13:1008946.
Ohe M, Shida H, Yamamoto J, et al. COVID-19 Treated with Minocycline and Saiko-keishi-to: A Case Report. Intern Med J. 2024;31:27-8.
Ohe M, Shida H, Yamamoto J, Seki M, Furuya K. Successful treatment with minocycline and Saiko-keishi-to for COVID-19. J CLIN EXP INVEST. 2023;14(2): em00815. https://doi.org/10.29333/jcei/12999
Yanagi K, Suzuki M, Hasegawa S. Shingata koronauirusu kansen-shō (COVID 19) no innaikansen ni taisuru keigairengyoto no hassho yobo koka [Preventive effect of Keigairengyoto on nosocomial infection of COVID 19]. Kampo to Saishin Chiryo, 2020;29(2):131–6.
Tsuchida N, Ohe M. Treatment with Kampo Medicine and Minocycline for Influenza. Intern Med J. 2025;32:162-3.
Ohe M. Drug Repurposing with Minocycline and Japanese Kampo Medicine for Mpox: Predicting Efficacy through In Silico Studies. Intern Med J. 2025;32:2-3.
Ohe M. Multidrug Treatment Using Kampo Medicine for Severe Fever with Thrombocytopenia Syndrome. Preprints 2025, 2025090637. https://doi.org/10.20944/preprints202509.0637.v1
Ohe M. Commentary: Combination Treatment Using Favipiravir for Crimean-Congo Hemorrhagic Fever. https://doi.org/10.51094/jxiv.1594
Ohe M. Treatment with Kampo medicine (Keigai-rengyo-to and Sho-saiko-to) with minocycline for Dengue virus. https://doi.org/10.51094/jxiv.3527
Qin S, Huang X, Qu S. Baicalin induces a potent innate immune response
to inhibit respiratory syncytial virus replication via regulating viral non-structural 1 and matrix RNA. Frontiers in immunology. 2022 Jun 23;13:907047.
Dong Y, Li H, Yao Z, et al. [The anti-respiratory syncytial virus (RSV) effect of Radix Glycyrrhizae in vitro]. Zhong Yao Cai. 2004 Jun;27(6):425-7. Chinese. PMID: 15524297.
Li WF, Wang X, Wang TH, et al. Application potential of luteolin in the treatment of viral pneumonia. Journal of Food Biochemistry. 2023;2023(1):1810503.
Lopes BR, da Costa MF, Ribeiro AG, et al. Quercetin pentaacetate inhibits in vitro human respiratory syncytial virus adhesion. Virus research. 2020 Jan 15;276:197805.
Sun YL, Zhao PP, Zhu CB, et al. Integrating metabolomics and network pharmacology to assess the effects of quercetin on lung inflammatory injury induced by human respiratory syncytial virus. Scientific Reports. 2023 May 17;13(1):8051.
de Souza FP, Seixas L, Pedro RP, et al. Investigation of the landscape of RSV M protein with quercetin and acetylated quercetin in the search for antivirals. Medical Research Archives. 2025;13(12).
Zhang S, Kemeng CA, Peipei ZH, et al. Unveiling the mechanism of kaempferol in RSV-induced lung inflammation through metabolomics and network pharmacology. Chinese Journal of Analytical Chemistry. 2025 Jul 1;53(7):100547.
Ling X, Zhou J, Jin T, et al. Acteoside attenuates RSV-induced lung injury by suppressing necroptosis and regulating metabolism. Frontiers in Pharmacology. 2022 Aug 19;13:870928.
Li Z, Jin G, Li X, et al. Targeting FTO/m6A epigenetics: Phillyrin dual-blocks respiratory syncytial virus replication and inflammation via NF-κB/STAT3 silencing. Phytomedicine. 2026 Jan 6:157803.
Du H, Ding J, Du Y, et al. Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Forsythia suspensa Extract Against Respiratory Syncytial Virus. International Journal of Molecular Sciences. 2025 May 29;26(11):5244.
Bawage SS, Tiwari PM, Pillai S, Dennis VA, Singh SR. Antibiotic minocycline prevents respiratory syncytial virus infection. Viruses. 2019 Aug 11;11(8):739.
Xu E, Park S, Calderon J, Cao D, Liang B. In silico identification and in vitro validation of repurposed compounds targeting the RSV polymerase. Microorganisms. 2023 Jun 18;11(6):1608.
ダウンロード
公開済
投稿日時: 2026-04-13 11:54:32 UTC
公開日時: 2026-05-27 04:03:14 UTC
ライセンス
Copyright（c）2026
Ohe, Masashi
この作品は、Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licenseの下でライセンスされています。
